LIME Study (LFB IVIg MMN Efficacy Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Motor Neuron Disease
Interventions
DRUG

Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)

DRUG

Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)

Trial Locations (18)

10126

Azienda Ospedaliero Universitaria San Giovanni Battista, Turin

13385

CHU de Marseille - Hôpital de La Timone, Marseille

15706

Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela

16132

Università di Genova - Ospedale San Martino, Genova

20089

IRCCS Istituto Clinico Humanitas, Milan

33604

CHU de Bordeaux -Hôpital Haut-Lévêque, Bordeaux

41013

Hospital Universitario Virgen del Rocio, Seville

42055

CHU de Saint Etienne - Hôpital Nord, Saint-Etienne

46026

Hospital Universitari i Politècnic La Fe, Valencia

59037

CHRU Lille - Hôpital Roger Salengro, Lille

69677

CHU de Lyon - Hôpital Pierre Wertheimer, Lyon

75651

CHU Paris - Hôpital Pitié Salpétrière, Paris

94010

CHU Créteil - Groupe Hospitalier Henri Mondor, Créteil

06202

CHU de Nice - Hôpital l'Archet, Nice

00168

Università Cattolica del Sacro Cuore, Roma

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

B15 2WB

Queen Elizabeth Hospital, Birmingham

SO16 6YD

Southampton General Hospital, Southampton

All Listed Sponsors
collaborator

TFS Trial Form Support

INDUSTRY

lead

Laboratoire français de Fractionnement et de Biotechnologies

INDUSTRY

NCT01951924 - LIME Study (LFB IVIg MMN Efficacy Study) | Biotech Hunter | Biotech Hunter